- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Oppenheimer initiates Aktis Oncology stock rating at Outperform | 9 | Investing.com | ||
| 19.08. | Wedbush initiates Aktis Oncology stock with outperform rating | 2 | Investing.com | ||
| 13.08. | Aktis Oncology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Aktis Oncology Inc.: Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 | 292 | GlobeNewswire (Europe) | Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumorsEnrolling... ► Artikel lesen | |
| 16.06. | Aktis is a Strong Buy at Raymond James on therapeutic platform | 7 | Seeking Alpha | ||
| 16.06. | This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday | 2 | Benzinga.com | ||
| AKTIS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 15.06. | Raymond James initiates Aktis Oncology stock coverage with buy rating | 19 | Investing.com | ||
| 21.05. | Aktis Oncology Inc.: Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors | 388 | GlobeNewswire (Europe) | Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including... ► Artikel lesen | |
| 11.05. | Aktis Oncology Inc.: Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 | 576 | GlobeNewswire (Europe) | Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate... ► Artikel lesen | |
| 04.05. | Aktis Oncology Inc.: Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 247 | GlobeNewswire (Europe) | Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumorsTwo-trial... ► Artikel lesen | |
| 30.03. | Aktis Oncology Inc.: Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results | 456 | GlobeNewswire (Europe) | Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical... ► Artikel lesen | |
| 24.02. | Aktis Oncology Inc.: Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate | 344 | GlobeNewswire (Europe) | U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing... ► Artikel lesen | |
| 13.01. | Aktis Oncology Inc.: Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 367 | GlobeNewswire (Europe) | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 25,500 | -0,78 % | Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. | ||
| INTELLIA THERAPEUTICS | 10,200 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNITYBIO | 6,140 | +1,49 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,569 | +1,41 % | Telix Pharmaceuticals Limited: Telix to Participate in UBS Global Biopharma Conference | Telix to Participate in UBS Global Biopharma Conference
MELBOURNE, Australia and INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| HELUS PHARMA | 7,950 | -2,21 % | XFRA NEW INSTRUMENTS AVAILABLE ON 06.10.2026 | The following instruments on XETRA do have their first trading 06.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.10.2026
Aktien
1 US98260Q2003 Wuxi Lead Intelligent... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,150 | -2,27 % | Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy | ||
| CAPRICOR | 8,064 | +1,18 % | Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA date | ||
| VANDA PHARMACEUTICALS | 3,578 | -1,43 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results | Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026Announced... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,100 | +4,27 % | Cartesian Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| LEGEND BIOTECH | 18,100 | -1,09 % | Legend Biotech Q3 2026 Earnings Call Transcript | ||
| KURA ONCOLOGY | 6,900 | +1,47 % | Kura Oncology übertrifft Gewinnerwartungen in Q3 2026 - Aktie legt nachbörslich zu | ||
| ANNOVIS BIO | 0,788 | +1,42 % | Annovis chairman invests $5M in $21M public offering | ||
| REIN THERAPEUTICS | 0,590 | 0,00 % | Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis | Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 2,720 | +1,12 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen |
AKTIS ONCOLOGY INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 17,470 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AKTIS ONCOLOGY INC finden Sie auf Wallstreet Online.